Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma

被引：0
|
作者：
Long, Yin
Yang, Qiong
Huang, Ziqi
He, Xiaodong
Huang, Jue
Liao, Jianguo
Chen, Yajin
Hu, Hai
Zhang, Lei
机构：
[1] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Oncol, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16221
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
    Hou, Zhenyu
    Zhu, Keyun
    Yang, Xuejiao
    Chen, Ping
    Zhang, Wei
    Cui, Yunlong
    Zhu, Xiaolin
    Song, Tianqiang
    Li, Qiang
    Li, Huikai
    Zhang, Ti
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [2] The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
    Bai, L.
    Bai, Y.
    Huang, M.
    Shao, G.
    Song, L.
    Sun, M.
    Wang, W.
    Wu, J.
    Xu, A.
    Huang, L.
    Liu, T.
    Liu, W.
    Wang, Z. M.
    Li, B.
    Xia, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S595 - S595
  • [3] Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma.
    Xing, Wenge
    Guo, Zhi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial
    Jiang, Lijuan
    Zheng, Xia
    Wei, Wensu
    Peng, Yulu
    Wang, Deling
    Zhang, Zhiling
    Guo, Shengjie
    Han, Hui
    Cai, Xiuyu
    Zhou, Fangjian
    Dong, Pei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction
    Peng, Zhi
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Tai, Yanfei
    Wang, Linna
    Zou, Jianjun
    Zhang, Yanqiao
    Shen, Lin
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3069 - 3078
  • [6] Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma
    Tsao, Che-Kai
    Agarwal, Neeraj
    Apolo, Andrea Borghese
    Lee, Karen M.
    Godbold, James H.
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    C-H Hsu
    T-S Yang
    C Hsu
    H C Toh
    R J Epstein
    L-T Hsiao
    P-J Chen
    Z-Z Lin
    T-Y Chao
    A-L Cheng
    British Journal of Cancer, 2010, 102 : 981 - 986
  • [8] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    Hsu, C-H
    Yang, T-S
    Hsu, C.
    Toh, H. C.
    Epstein, R. J.
    Hsiao, L-T
    Chen, P-J
    Lin, Z-Z
    Chao, T-Y
    Cheng, A-L
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 981 - 986
  • [9] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [10] Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom
    Trojan, Joerg
    Cebon, Jonathan
    Liem, Andre K.
    Lipton, Lara
    Gupta, Charu
    Wu, Benjamin
    Bass, Michael
    Hollywood, Ellen
    Ma, Jennifer
    Bradley, Margaret
    Litten, Jason
    Saltz, Leonard B.
    ONCOLOGIST, 2017, 22 (07): : 780 - +
12345